

# Richard J Weaver

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/688756/publications.pdf>

Version: 2024-02-01

19  
papers

1,078  
citations

623574

14  
h-index

794469

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 131-148.	21.5	153
2	The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. <i>Toxicology and Applied Pharmacology</i> , 2020, 391, 114915.	1.3	6
3	A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor $\beta$ agonists. <i>Journal of Biological Chemistry</i> , 2019, 294, 3720-3734.	1.6	17
4	Today's Challenges to De-Risk and Predict Drug Safety in Human "Mind-the-Gap". <i>Toxicological Sciences</i> , 2019, 167, 307-321.	1.4	78
5	Trovafloxacin-Induced Liver Injury: Lack in Regulation of Inflammation by Inhibition of Nucleotide Release and Neutrophil Movement. <i>Toxicological Sciences</i> , 2019, 167, 385-396.	1.4	13
6	Kinetic characterization of bile salt transport by human NTCP (SLC10A1). <i>Toxicology in Vitro</i> , 2018, 46, 189-193.	1.1	16
7	Human OATP1B1 (SLCO1B1) transports sulfated bile acids and bile salts with particular efficiency. <i>Toxicology in Vitro</i> , 2018, 52, 189-194.	1.1	12
8	Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 767-782.	1.5	30
9	Stem cell-derived models to improve mechanistic understanding and prediction of human drug-induced liver injury. <i>Hepatology</i> , 2017, 65, 710-721.	3.6	54
10	A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. <i>Archives of Toxicology</i> , 2017, 91, 1385-1400.	1.9	85
11	Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation Plans. <i>BioMed Research International</i> , 2016, 2016, 1-20.	0.9	44
12	Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1780-1793.	1.7	45
13	Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. <i>Archives of Toxicology</i> , 2016, 90, 2979-3003.	1.9	50
14	Development and use of in vitro alternatives to animal testing by the pharmaceutical industry 1980-2013. <i>Toxicology Research</i> , 2015, 4, 1297-1307.	0.9	49
15	Comparative Proteomic Characterization of 4 Human Liver-Derived Single Cell Culture Models Reveals Significant Variation in the Capacity for Drug Disposition, Bioactivation, and Detoxication. <i>Toxicological Sciences</i> , 2015, 147, 412-424.	1.4	73
16	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of <i>In Vitro</i> Models. <i>Applied in Vitro Toxicology</i> , 2015, 1, 175-186.	0.6	5
17	PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. <i>Toxicology and Applied Pharmacology</i> , 2014, 276, 73-81.	1.3	61
18	In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. <i>Chemical Research in Toxicology</i> , 2012, 25, 1616-1632.	1.7	197

#	ARTICLE	IF	CITATIONS
19	Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. <i>Chemico-Biological Interactions</i> , 2011, 192, 65-71.	1.7	90